Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 103-109

  Parihar, Mayur ^a   Kumar, J Ashok ^a   Sitaram, Usha ^a   Balasubramanian, Poonkuzhali ^a   Abraham, Aby ^a   Viswabandya, Auro ^a   George, Biju ^a   Mathews, Vikram ^a   Srivastava, Alok ^a   Srivastava, Vivi M ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

AML; C KIT mutation; FLT3 mutation; JAK2 mutation; T(8; 21)

Indexed keywords

CD135 ANTIGEN; CD19 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME STRUCTURE; CHROMOSOME TRANSLOCATION; DYSPLASIA; EOSINOPHILIA; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; INDIA; LOSS OF A SEX CHROMOSOME; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MONOSOMY 17; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SEX CHROMOSOME; TERTIARY HEALTH CARE; TRISOMY 15; TRISOMY 4; TRISOMY 8;

ADOLESCENT; ADULT; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETIC ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HOSPITALS, UNIVERSITY; HUMANS; INDIA; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84855457891     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.603447     Document Type: Article

References (49)

1. G rimwade D, Walker H, Oliver F, et al. Th e importance of diagnosticcytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Th e Medical Research Council Adult and Children ' s Leukaemia Working Parties. Blood 1998;92:2322-2333. (Pubitemid 28452973)
2. C heng Y, Wang Y, Wang H, et al. Cytogenetic profi le of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 2009;23:1801-1806.
3. H arrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674-2681.
4. S ekeres MA, Peterson B, Dodge RK, et al. Diff erences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004;103:4036-4042. (Pubitemid 38685341)
5. E rickson P, Gao J, Chang KS, et al. Identifi cation of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992;80:1825-1831.
6. M arcucci G, Caligiuri MA, Bloomfi eld CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000;18:768-780.
7. S peck NA, Stacy T, Wang Q, et al. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res 1999;59: 1789s - 1793s. (Pubitemid 29165256)
8. E lagib KE, Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 2007;251:179-186. (Pubitemid 46669791)
9. T enen DG, Hromas R, Licht JD, et al. Transcription factors, normal myeloid development, and leukemia. Blood 1997;90:489-519. (Pubitemid 27299089)
10. Y uan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001;98:10398-10403. (Pubitemid 32803031)
11. K uchenbauer F, Schnittger S, Look T, et al. Identifi cation of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006;134:616-619. (Pubitemid 44253604)
12. A ppelbaum FR, Kopecky KJ, Tallman MS, et al. Th e clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006;135:165-173. (Pubitemid 44401613)
13. B ao L, Wang X, Ryder J, et al. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classifi cation: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol 2006;77:35-45. (Pubitemid 43876203)
14. J ohansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer 1991;3:1-7.
15. Korf BR. Overview of clinical cytogenetics. Curr Protoc Hum Genet 2001Ch. 8:Unit 8.1.
16. Schaff er L, Slovak M, Campbell L. ISCN 2009: an international system for human cytogenetic nomenclature. Basel: Karger; 2009.
17. A morim MR, Vargas FR, Llerena JC Jr, et al. DNA extraction from fi xed cytogenetic cell suspensions. Genet Mol Res 2007;6: 500-503. (Pubitemid 350096884)
18. Huang Q, Chen W, Gaal KK, et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 2008;142:489-492. (Pubitemid 351962181)
19. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-2439. (Pubitemid 32291491)
20. P ollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic signifi cance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010;115:2372-2379.
21. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
22. Veneri D, Capuzzo E, de Matteis G, et al. Comparison of JAK2V617F mutation assessment employing diff erent molecular diagnostic techniques. Blood Transfus 2009;7:204-209.
23. Creutzig U, Berthold F, Boos J, et al. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Padiatr 2001;213:175-185. (Pubitemid 32801569)
24. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24: 4499-4506. (Pubitemid 46646248)
25. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006;107:116-124. (Pubitemid 43939038)
26. Rowley JD. Identifi caton of a translocation with quinacrine fl uorescence in a patient with acute leukemia. Ann Genet 1973;16: 109-112.
27. Vardiman JW, Th iele J, Arber DA, et al. Th e 2008 revision of the World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
28. Ahmad F, Dalvi R, Das BR, et al. Specifi c chromosomal aberrations in de novo acute myeloid leukemia: a comparative analysis of results with a report of three novel chromosomal rearrangements t(7;14) (q35;q13), t(8;18)(p11.2;q12), t(13;15) in Indian population. Cancer Detect Prev 2008;32:168-177.
29. X iao Z, Liu S, Liu X, et al. Tetraploidy or near-tetraploidy clones with double 8;21 translocation: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22). Haematologica 2005;90:413-414. (Pubitemid 40388998)
30. Lin P, Chen L, Luthra R, et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 2008;21:1029-1036.
31. A cute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Fran ç ais de Cytog én é tique H é matologique. Cancer Genet Cytogenet 1990;44:169-179.
32. H aferlach T, Bennett JM, Lö ffl er H, et al. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymphoma 1996;23:227-234. (Pubitemid 27029335)
33. R ubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution ' s experience. Leukemia 2002;16:2072-2077. (Pubitemid 35203450)
34. Nishii K, Usui E, Katayama N, et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 2003;17:731-737. (Pubitemid 36519369)
35. Schlenk RF, Benner A, Krauter J, et al. Individual patient databased meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004;22:3741-3750. (Pubitemid 41102131)
36. L ai Y-Y, Qiu J-Y, Jiang B, et al. Characteristics and prognostic factors of acute myeloid leukemia with t(8;21)(q22;q22). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005;13:733-740.
37. K houry H, Dalal BI, Nantel SH, et al. Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 2004;17:1211-1216. (Pubitemid 39312947)
38. H urwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182-3188. (Pubitemid 23004523)
39. D e J, Zanjani R, Hibbard M, et al. Immunophenotypic profi le predictive of KIT activating mutations in AML1-ETO leukemia. Am J Clin Pathol 2007;128:550-557. (Pubitemid 47584431)
40. K ita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80: 470-477.
41. C are RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003;121:775-777. (Pubitemid 36718195)
42. L asa A, Carricondo MT, Carnicer MJ, et al. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica 2006;91:1283-1284. (Pubitemid 44408448)
43. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006;20: 965-970. (Pubitemid 43797286)
44. Th iede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-4020. (Pubitemid 43726809)
45. S uzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-2861. (Pubitemid 41510764)
46. Iwanaga E, Nanri T, Matsuno N, et al. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica 2009;94:433-435.
47. Billstr ö m R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol 1997;59:47-52. (Pubitemid 27321174)
48. T allman MS, Hakimian D, Shaw JM, et al. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993;11:690-697. (Pubitemid 23105677)
49. B yrd JC, Mró z ek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100(Suppl. 1): Abstract 4325.